Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
This is a phase 3, multicenter, randomized, placebo-controlled, double- blinded clinical trial investigating the efficacy and safety of maximum tolerated dose (MTD) of tirzepatide (10 mg or 15 mg) administered once weekly (QW) subcutaneously compared with placebo for body weight management, in participants who have obesity, or overweight with at least 1 obesity-related complication (excluding type 2 diabetes), and with at least 5% weight reduction following a 12-week intensive lifestyle intervention lead-in
Using the lowest effective dose This is often the most medically sensible version of what people are trying to describe
EllieMD is a telehealth company and subscription-based service that connects consumers to online medical providers for prescriptions to its customized medications
In combination with diet and exercise, Ozempic can help to improve glycaemic control
The SURMOUNT-1 trial showed tirzepatide produced mean weight loss ranging from 15% to 21% depending on dose
US$ 25.34
US$ 20.92
US$ 23.93
